Home・Aktien・Protagonist Therapeutics Inc
Search

Protagonist Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

149.76 2.67

Starkes Kaufsignal

Kursupdate 10. Aug. 2026, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

145.87

Max

151.35

Schlüsselkennzahlen

By Trading Economics

Einkommen

-82M

3.8M

Verkäufe

49M

56M

KGV

Branchendurchschnitt

131.197

68.51

EPS

0.05

Gewinnspanne

6.711

Angestellte

131

EBITDA

46M

2.7M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+6.12% upside

Dividenden

By Acuity

Nächstes Ergebnis

11. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.1B

8.5B

Vorheriger Eröffnungskurs

147.09

Vorheriger Schlusskurs

149.76

Nachrichtenstimmung

By Acuity

72%

28%

302 / 340 Ranking in Healthcare

Protagonist Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Aug. 2026, 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

Lesen

6. Aug. 2026, 19:52 UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

Lesen

5. Aug. 2026, 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

Lesen

4. Aug. 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

Lesen

3. Aug. 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

Lesen

31. Juli 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

Lesen

30. Juli 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

Lesen

29. Juli 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

Lesen

28. Juli 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

Lesen

27. Juli 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

Lesen

22. Juli 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

Lesen

21. Juli 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

Lesen

20. Juli 2026, 19:41 UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Lesen

Peer-Vergleich

Kursveränderung

Protagonist Therapeutics Inc Prognose

Kursziel

By TipRanks

6.12% Vorteil

12-Monats-Prognose

Durchschnitt 159.18 USD  6.12%

Hoch 186 USD

Tief 113 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Protagonist Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

11

Buy

0

Halten

0

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Protagonist Therapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

302 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Andere Aktien aus dem Sektor

JNJ

Johnson and Johnson

261.83

↑ +0.98%

ABBV

AbbVie Inc

247.74

↑ +0.75%

UNH

UnitedHealth Group Inc

408.59

↑ +0.41%

NVS

Novartis AG

156.8

↑ +0.48%

AZN

AstraZeneca PLC

161.88

↑ +0.36%
help-icon Live chat